在患有多发性硬化症的黑人患者中,酸盐与神素-1-酸盐受体调节剂的相对有效性
Sophia Woodson1, Edward J Gettings2, Chu-Yueh Guo3
1University Hospitals, Cleveland, OH, USA.
Neurology and therapy
|June 16, 2025
概括
酸盐和基-1-酸盐 (S1P) 受体调节剂在减少患有多发性硬化症 (MS) 的黑人复发方面表现出类似的有效性. 在两个治疗组中,超过72%的患者在24个月内没有复发.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 不成比例地影响黑人,他们经历了更严重的疾病和更高的复发率.
- 酸盐和基-1-酸盐 (S1P) 受体调节剂是复发性多发性硬化症的常见口腔疾病修饰疗法 (DMT).
- 这些DMT在患有MS (PwMS) 的黑人患者中的比较有效性仍未得到充分研究.
研究的目的:
- 为了比较黑色PwMS中烟酸与S1P受体调节器的有效性,使用现实世界的数据.
- 为了评估治疗结果,特别是年度复发率 (ARR) 和第一次复发的时间.
主要方法:
- 从科莫多健康索赔数据库 (2017年1月至2023年4月) 索赔数据的回顾性分析.
- 包括年龄在18-64岁的黑人PwMS,MS诊断和食用烟酸或S1P受体调节器的处方要求.
- 倾向性得分匹配 (2:1) 和反向概率加权被用于平衡基线特征.
主要成果:
- 这项研究包括1664名黑色PwMS (1231名吸烟剂,433名S1P调节器).
- 在指数后的年度复发率在烟酸和S1P组之间是可比的 (比率比率=1.18,p=0.423).
- 卡普兰-梅尔分析显示,24个月后,类似的无复发比例 (72.6%的烟酸,74.7%的S1P调节器;p=0.152).
结论:
- 烟酸和S1P受体调节剂在现实环境中在减少黑人PWMS复发方面表现出类似的有效性.
- 在这两组患者中,超过72%的患者在24个月后仍然没有复发.
- 这些发现提供了有价值的现实世界的证据,为黑人PwMS的治疗决策提供了信息,解决了在临床试验中代表人数不足的差距.
更多相关视频
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
4.2K
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.4K
相关概念视频
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K
